Trade Abbvie - ABBV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.26 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.65 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 182.57 |
| Open | 184.94 |
| 1-Year Change | 30.72% |
| Day's Range | 184.8 - 186.7 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 181.72 | 5.67 | 3.22% | 176.05 | 185.94 | 170.94 |
| Jul 24, 2024 | 176.10 | 3.41 | 1.97% | 172.69 | 176.51 | 172.69 |
| Jul 23, 2024 | 173.02 | 0.06 | 0.03% | 172.96 | 174.50 | 172.67 |
| Jul 22, 2024 | 173.46 | 1.14 | 0.66% | 172.32 | 174.41 | 171.95 |
| Jul 19, 2024 | 172.24 | 0.43 | 0.25% | 171.81 | 173.58 | 171.10 |
| Jul 18, 2024 | 171.02 | -2.78 | -1.60% | 173.80 | 176.53 | 170.30 |
| Jul 17, 2024 | 175.17 | 5.64 | 3.33% | 169.53 | 175.67 | 169.53 |
| Jul 16, 2024 | 169.05 | 0.99 | 0.59% | 168.06 | 169.73 | 167.18 |
| Jul 15, 2024 | 167.94 | -0.69 | -0.41% | 168.63 | 170.26 | 167.32 |
| Jul 12, 2024 | 170.16 | -0.30 | -0.18% | 170.46 | 171.47 | 169.81 |
| Jul 11, 2024 | 169.84 | 2.59 | 1.55% | 167.25 | 170.27 | 167.25 |
| Jul 10, 2024 | 168.06 | 0.96 | 0.57% | 167.10 | 168.26 | 165.99 |
| Jul 9, 2024 | 167.98 | 1.31 | 0.79% | 166.67 | 168.38 | 164.80 |
| Jul 8, 2024 | 166.43 | 0.16 | 0.10% | 166.27 | 167.56 | 165.22 |
| Jul 5, 2024 | 167.08 | 2.43 | 1.48% | 164.65 | 167.24 | 163.53 |
| Jul 3, 2024 | 163.70 | -2.09 | -1.26% | 165.79 | 166.93 | 163.45 |
| Jul 2, 2024 | 165.88 | -2.45 | -1.46% | 168.33 | 168.36 | 165.38 |
| Jul 1, 2024 | 170.23 | -0.81 | -0.47% | 171.04 | 173.73 | 169.45 |
| Jun 28, 2024 | 171.24 | 2.03 | 1.20% | 169.21 | 171.74 | 168.92 |
| Jun 27, 2024 | 168.56 | -2.04 | -1.20% | 170.60 | 171.42 | 167.66 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AbbVie Company profile
AbbVie Inc. is a research-based pharmaceutical company, specialising in the discovery and development of biopharmaceuticals and small molecule drugs. With a team of around 29,000 scientists, researchers, manufacturing specialists and communications professionals across the globe, the company introduces new approaches to treating chronic conditions and life-threatening health issues. In 2019, AbbVie was ranked 96th on the Fortune 500 list of America’s biggest companies. More than 30 million patients in over 170 countries are treated by AbbVie’s medicines annually.
Headquartered in North Chicago, Illinois, AbbVie has 22 primary research and manufacturing facilities around the world. The company’s research centres are in the US, Germany and Japan; and its manufacturing sites are located in the USA, Puerto Rico, Ireland, Germany, Italy and Singapore.
The company produces medicines aimed at treating autoimmune diseases, cancers, viruses (including hepatitis C and HIV), neurological and metabolic disorders. According to the Wall Street Journal, in 2016, a specialty drug ibrutinib, retailed by the company, cost from $116,600 to $155,400 a year wholesale in the US. AbbVie estimates global sales of the drug at $5 billion in 2020.
The history of AbbVie started in 2013 when Abbott Laboratories split into two publicly traded companies. One, using the old company name, was to specialise in medical equipment and devices and nutritional products; the other, AbbVie, was to be a research-driven pharmaceutical manufacturer. From the start, AbbVie was interested in acquisitions: in 2014, it acquired ImmuVen for an undisclosed amount, and in 2015, AbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers.
Presently, the AbbVie share price is listed on the New York Stock Exchange (NYSE). It is also a constituent of both the S&P 100 and 500 indices. In 2018, AbbVie reported its annual revenues of over $32.75 billion. During the same year, the ABBV stock price hit an all-time high of $123. As of July 2019, the company’s market capitalisation was set at around $106.13 billion.
Get the latest news on the Abbvie share price and stay on top of the ABBV share price chart with Capital.com.
| Industry: | Pharmaceuticals (NEC) |
1 N Waukegan Rd
NORTH CHICAGO
ILLINOIS 60064
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com